Navigation Links
BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes

SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) announced today the expiration and final results of the previously announced cash tender offer by its operating partnership, BioMed Realty, L.P., for any and all of its outstanding 4.50% Exchangeable Senior Notes due 2026 (the "Notes").

As of midnight, New York City time, on Tuesday, December 8, 2009, the scheduled expiration date of the tender offer, $61,270,000.00 in aggregate principal amount of the Notes, representing approximately 57% of the aggregate principal amount of the outstanding Notes prior to the tender offer, had been validly tendered and not properly withdrawn in the tender offer. All Notes validly tendered and not properly withdrawn in the tender offer have been accepted for payment by BioMed Realty, L.P. and will be cancelled.

The consideration to be paid for each $1,000 principal amount of the Notes was $1,000, plus accrued and unpaid interest up to, but not including, the date of purchase. Payment of the aggregate consideration of $61,806,112.50, including accrued and unpaid interest, will be made on the validly tendered Notes in accordance with the terms of the tender offer on December 11, 2009. After giving effect to the purchase of the tendered Notes, $46,150,000.00 aggregate principal amount of the Notes remains outstanding.

This announcement is for informational purposes only and is not an offer to buy, or the solicitation of an offer to sell, any Notes. The tender offer was made solely by and subject to the terms and conditions set forth in the Schedule TO (including the offer to purchase and related letter of transmittal) that was filed by BioMed Realty, L.P. with the Securities and Exchange Commission.

BioMed retained Credit Suisse Securities (USA) LLC to serve as the dealer manager and D.F. King & Co., Inc. to serve as the information agent for the tender offer.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in 69 properties, representing 114 buildings with approximately 10.5 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at

This press release contains forward-looking statements based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: BioMed's offer to purchase any and all of the Notes in the tender offer; adverse economic or real estate developments in the life science industry or in our target markets, including the ability of our tenants to obtain funding to run their businesses; our failure to obtain necessary outside financing on favorable terms or at all, including the continued availability of our unsecured line of credit; general economic conditions, including downturns in the national and local economies; volatility in financial and securities markets; defaults on or non-renewal of leases by tenants; our inability to compete effectively; increased interest rates and operating costs; our inability to successfully complete real estate acquisitions, developments and dispositions; risks and uncertainties affecting property development and construction; our failure to successfully operate acquired properties and operations; our failure to maintain our status as a REIT; government approvals, actions and initiatives, including the need for compliance with environmental requirements; and changes in real estate, zoning and other laws and increases in real property tax rates. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Except as required by law, the company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.

SOURCE BioMed Realty Trust, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
2. BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends
3. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
4. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
5. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
6. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
7. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
8. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
9. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
10. Environmental Tectonics Corporations BioMedical Division Announces New Contract
11. Avery Biomedical Devices, Inc. Appoints Elefteriades to its Board of Directors
Post Your Comments:
(Date:10/12/2015)... cell surface marker detection market ... to a new report by Grand View Research, Inc. This ... of oncology diseases and other cell-associated disorders. --> ... USD 6.49 billion by 2022, according to a new report ... be attributed to rise in incidence of oncology diseases and ...
(Date:10/12/2015)... 2015  Patara Pharma, a clinical-stage biotechnology company ... and conditions, today announced the closing of a ... with the close of its sale of preferred ... Security Agreement with Silicon Valley Bank whereby the ... will use the funds from the financing to ...
(Date:10/12/2015)... 12, 2015 VolitionRx Limited (NYSE MKT: ... study of its NuQ ® blood-based test for early ... of Clinical Epigenetics , the official journal of the ... with Lund University, Sweden ... PhD, Professor of Surgery and Vice-Dean, Faculty of Medicine. ...
(Date:10/12/2015)... ... October 12, 2015 , ... LifeTrak , a leader in ... Zoom, the world’s first amphibious fitness tracker that seeks to meet the needs of ... accurate heart rate monitoring both in water and on land, making it ...
Breaking Biology Technology:
(Date:10/12/2015)... Research and Markets ( ) ... Recognition Market by Component (Hardware & Software), Product ... Industry (Travel & Immigration, Military & Defense, & ... report to their offering. ... Market worth 3627.90 Million USD by 2020 ...
(Date:10/8/2015)... LAKE CITY , 8. Oktober 2015 ... TRCK), ein global tätiges Unternehmen des Bereiches ... einem Vertrag mit der Gefängnisbehörde Virginias (Department ... dessen Rahmen elektronische Überwachungsdienste für alle Strafen ... Derek Cassell , Präsident für den ...
(Date:10/7/2015)... NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... long- term executive at American Express has been appointed ... ) ("NXT-ID" or the "Company"), a biometric authentication company ... of the Wocket® smart wallet announces Mr. Stanley ...
Breaking Biology News(10 mins):